ELI LILLY & Co
Close on Nov 2, 2026Market cap $1.33TP/E 45.8Yield 0.44%
Eli Lilly Baqsimi (nasal glucagon) by Year
Baqsimi (nasal glucagon) — Worldwide revenue ($M) [legacy separate disclosure] ($M)
Eli Lilly Baqsimi (nasal glucagon): $29.1M in FY2024, down 95.7% from a year earlier. No newer figure appears in the documents we track.
Where the FY2024 figure comes from
“|| Baqsimi | 2.5 | 26.7 | 29.1 | 677.6 | (96)”
Source: Form 10-K FY2024 (filed 2025-02-19) ↗
Reported in Form 10-Q / 10-K Note 2 & MD&A (legacy separate product disclosure prior to FY2025 reorganization).
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Baqsimi (nasal glucagon) — Worldwide revenue ($M) [legacy separate disclosure] ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2024 | Dec 31, 2024 | 29.1 | -95.7% | Form 10-K FY2024 (filed 2025-02-19) ↗ |
| FY2023 | Dec 31, 2023 | 678 | +386.4% | Form 10-K FY2023 (filed 2024-02-21) ↗ |
| FY2022 | Dec 31, 2022 | 139 | – | Form 10-K FY2023 (filed 2024-02-21) ↗ |
| FY2020 | Dec 31, 2020 | 76.1 | +239.7% | Earnings Release (Form 8-K FY2020Q4 EX-99.1) (filed 2021-01-29) ↗ |
| FY2019 | Dec 31, 2019 | 22.4 | – | Earnings Release (Form 8-K FY2020Q4 EX-99.1) (filed 2021-01-29) ↗ |
Breakdown
What makes up baqsimi (nasal glucagon)
Cite this data
StockData. (2026). Eli Lilly Baqsimi (nasal glucagon) ($M), annual FY2019–FY2024 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/med-baqsimi-ww
See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.